Yojana Rodríguez-Humbert, a Florida mother who lost her 14-month-old daughter Kaya to an ultra-rare genetic condition designated as SPLIS, has taken her advocacy to the U.S. Capitol. Following her family's struggle to manage thirty daily medications and a devastating diagnosis of a condition with only 43 known global cases, Rodríguez-Humbert is pressing federal and state lawmakers for earlier genetic screening mandates and expanded diagnostic access.
Rare SPLIS Disorder Requires Early Genetic Screening
- SPLIS: An extremely rare genetic disorder causing severe health complications, requiring complex multi-drug management.
- Genetic Screening: Routine newborn screenings typically cover around 60 common conditions, leaving thousands of rare disorders—such as SPLIS—undetected until acute symptoms manifest.
- Preventative Advocacy: Early clinical identification and genetic counseling can provide families with prognostic clarity and coordinated pediatric care prior to a medical crisis.
The Legislative Push in Washington and Tallahassee
Rodríguez-Humbert's campaign inside congressional offices follows the 2025 passage of Florida's Sunshine Genetics Act, legislation designed to expand parental access to broader genetic testing options for newborns. Despite these state-level advancements, the family's experience highlights persistent systemic gaps. Kaya was born in 2023 appearing completely healthy, though initial newborn screening flags prompted further investigation.
Working alongside the American Kidney Fund and through her newly established organization, Kaya Girl Legacy, Rodríguez-Humbert is advocating for federal research funding and legislative support targeting rare renal and genetic disorders. Her advocacy centers on bridging the gap between genomic discoveries and clinical implementation, ensuring that pediatric specialists and genetic counselors are accessible before families reach emergency interventions.
Epidemiological Context of Ultra-Rare Pediatric Syndromes
Ultra-rare genetic diseases present distinct diagnostic and regulatory challenges within modern healthcare frameworks. While standard state newborn screening panels screen for approximately 60 congenital and metabolic conditions, over 7,000 distinct rare genetic disorders have been cataloged in medical literature. The clinical timeline from birth to definitive diagnosis often involves extensive diagnostic odyssey protocols, during which infants may experience rapid physiological deterioration without a definitive molecular diagnosis.
| Clinical Parameter | Standard Newborn Screening | Extended Genomic Screening (e.g., Sunshine Genetics Act) |
|---|---|---|
| Target Conditions | ~60 high-prevalence metabolic and congenital disorders | Thousands of rare monogenic and genetic conditions |
| Mechanism of Action | Biochemical assays, tandem mass spectrometry | Next-generation DNA sequencing (NGS), panel testing |
| Diagnostic Timeline | Days to weeks post-birth | Dependent on clinical authorization and panel depth |
Pediatric Specialists Must Evaluate Specific Infant Symptoms
Expanded panels are generally not contraindicated for infants, but interpretation requires specialized genetic counseling to contextualize variants of uncertain significance (VUS)—genetic changes where the clinical impact is currently unknown. Immediate medical evaluation by a pediatric specialist is warranted if an infant exhibits failure to thrive, unexplained metabolic acidosis, developmental regression, or recurrent treatment-resistant symptoms.
The Path Forward for Rare Disease Families
The core objective of the legislative initiatives championed by Rodríguez-Humbert remains focused on shifting the paradigm from reactive emergency intervention to proactive genetic literacy. As federal lawmakers review proposals for enhanced rare disease research funding, the primary clinical challenge persists in standardizing access to comprehensive genomic sequencing panels across diverse healthcare systems.
References
- American Kidney Fund. Rare Kidney Disease Advocacy Initiatives and Legislative Updates.
- Florida Legislature. Sunshine Genetics Act, Legislative Record and Implementation Guidelines.
